Erythropoiesis inhibitor in the plasma of patients with hemopoietic dysplasias
Gudim, V.I.; Korobkin, A.V.; Turbina, N.S.; Tsvetova, N.V.; Ivanova, V.S.
Terapevticheskii Arkhiv 61(7): 48-52
1989
ISSN/ISBN: 0040-3660 PMID: 2588143 Document Number: 338089
Altogether 21 patients were examined for an erythropoiesis inhibitor contained by the IgG fraction of the blood plasma. All these patients suffered from hemopoiesis depression. The inhibitor identified in the immunoglobulin fraction of the blood plasma of 40% of the patients manifested itself at the stage of erythroid precursors of bone marrow cells. The role of the humoral inhibitor in the development of erythropoietic disorders in these patients is under discussion.
Document emailed within 1 workday
Related Documents
Bielecki, M.; Gruszecki, W.; Wojtowicz, Z. 1970: Erythropoietic activity after stimulation of the hemopoietic system with cobalt chloride and its inhibition by an inhibitor of erythropoiesis Wiadomosci Lekarskie 23(24): 2171-2176Laurell, M.; Stenflo, J. 1989: Protein C inhibitor from human plasma: characterization of native and cleaved inhibitor and demonstration of inhibitor complexes with plasma kallikrein Thrombosis and Haemostasis 62(3): 885-891
García, Y.; Gudim, I.V.; Noyola, M.C.; Callejas, R.J. 1984: Circulating inhibitor of erythropoiesis in patients with acquired aplastic anemia Sangre 29(1): 15-20
Saito, A.; Suzuki, I.; Chung, T.G.; Okamoto, T.; Hotta, T. 1986: Separation of an inhibitor of erythropoiesis in "middle molecules" from hemodialysate from patients with chronic renal failure Clinical Chemistry 32(10): 1938-1941
Zakharov, I.M.; Tabarchuk, A.D.; Ershov, V.N. 1973: Role of bone marrow nuclei in the formation of a humoral inhibitor of erythropoiesis Patologicheskaia Fiziologiia i Eksperimental'naia Terapiia 17(3): 61-62
Chayakulkeeree, M.; Poovipirom, N.; Siengwattana, P.; Maneerattanaporn, M. 2015: Effect of proton pump inhibitor on plasma voriconazole concentration in Thai patients Journal of the Medical Association of Thailand 98(3): 232-237
Neal, W.A.; Lewis, J.P.; Welch, E.T.; Lutcher, C.L.; Moores, R.R.; Wright, C.S. 1979: Inhibition of erythropoiesis by plasma component(s) from sheep, goats, and rabbits American Journal of Veterinary Research 40(4): 493-497
Boutsikas, G.; Terpos, E.; Markopoulos, A.; Papatheodorou, A.; Stefanou, A.; Georgiou, G.; Galani, Z.; Komninaka, V.; Telonis, V.; Anagnostopoulos, I.; Dimitrakopoulou, L.; Anargyrou, K.; Tsionos, K.; Christoulas, D.; Gonianaki, M.; Giannikos, T.; Kokoris, S.; Konstantopoulos, K.; Meletis, J.; Angelopoulou, M.K.; Travlou, A.; Vassilakopoulos, T.P. 2017: Protein Z (PZ) and plasminogen activator inhibitor-1 (PAI-1) plasma levels in patients with previously untreated Hodgkin lymphoma (HL) Journal of BUON: Official Journal of the Balkan Union of Oncology 22(4): 1022-1031
España, F.; Estelles, A.; Griffin, J.H.; Aznar, J. 1991: Interaction of plasma kallikrein with protein C inhibitor in purified mixtures and in plasma Thrombosis and Haemostasis 65(1): 46-51
Flisiak, R.; Maxwell, P.; Prokopowicz, D.; Timms, P.M.; Panasiuk, A. 2002: Plasma tissue inhibitor of metalloproteinases-1 and transforming growth factor beta 1--possible non-invasive biomarkers of hepatic fibrosis in patients with chronic B and C hepatitis Hepato-Gastroenterology 49(47): 1369-1372
Macchi, H.; Fiasse, R.; Reynaert, M.; Desager, J.P.; Dive, C. 1982: Effect of ranitidine (inhibitor of H2 receptors) after I.v. injection to patients treated in an intensive care unit: control of gastric acid secretion and estimation of drug plasma levels Archives Internationales de Pharmacodynamie et de Therapie 256(2): 306-307
Hirschfield, G. 2001: Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT Study)--a rebuttal Thrombosis and Haemostasis 85(1): 189-190
Perugini, S.; Patrignani, A.; Sternieri, E.; Mucci, P. 1971: Prematurely labeled bilirubin. I. Incorporation of glycine-2- 14 C and -ALA-3,5- 3 H into plasma bilirubin, erythrocyte heme and globin during normal and stimulated erythropoiesis Haematologica 56(1): 21-35
Bolten, W.W. 2003: In high risk patients cyclooxygenase inhibitor plus proton pump inhibitor MMW Fortschritte der Medizin 145(5): 9
Han, X.M.; Chen, Z.Q.; Mao, H.M. 1990: Determination of plasma tissue type plasminogen activator and plasminogen activator inhibitor activity in patients with ischemic stroke Zhonghua Nei Ke Za Zhi 29(9): 544-546; 575-576
Ohno, Y. 1976: Effects of androgens on erythropoiesis. in vivo and in vitro actions of androgens on erythropoiesis Nihon Ketsueki Gakkai Zasshi: Journal of Japan Haematological Society 39(2): 149-157
Frindel, E.; Masse, A.; Pradelles, P.; Volkov, L.; Rigaud, M. 1992: Correlation of endogenous acetyl-ser-asp-lys-pro plasma levels in mice and the kinetics of pluripotent hemopoietic stem cells entry into the cycle after cytosine arabinoside treatment: fundamental and clinical aspects Leukemia 6(6): 599-601
Zucker, S.; Lysik, R.M.; Chikkappa, G.; Glucksman, M.J.; Gomez-Reino, J.; DiStefano, J.F. 1980: Very low density lipoprotein hematopoiesis inhibitor from rat plasma Experimental Hematology 8(7): 895-905
Teterina, N.F.; Okuneva, G.N.; Anoshina, V.M. 1973: Study of bone marrow erythropoiesis in patients with tetralogy of Fallot Kardiologiia 13(8): 117-121
Simonianová, E.; Tomásová, H.; Mydlilová, A.; Zoban, P. 1993: C1-inhibitor plasma levels in neonates and mothers during labor Ceskoslovenska Pediatrie 48(12): 707-710